1. NTRK1 (1Q21-Q22) encodes TRKA protein. When rearrangement occurs, it leads to abnormal cell proliferation. Trk inhibitors and crizotinib can reduce the phosphorylation of fusion protein and inhibit cell proliferation.
2. New therapeutic targets in lung adenocarcinoma.